CEO Bobby Gaspar, MD, PhD, discusses the gene therapy developer’s streamlined pipeline and retooled manufacturing approach with GEN Edge
Bobby Gaspar, MD, PhD, leads Orchard Therapeutics as it shifts its manufacturing approach to investing in next-generation technologies; and narrows its near-term priority R&D pipeline programs to four. In May, Orchard cut about 25% of its workforce, ended development of a manufacturing site in Fremont, CA; and shut down a lab-office site in Menlo Park, CA. [Orchard Therapeutics]
CEO Bobby Gasoar, MD, PhD, made his presence felt at Orchard Therapeutics in May, leading the company in carrying out a strategic plan that included eliminating about 25% of its workforce, or 60 jobs, and narrowing its near-term R&D pipeline programs to four . . .
